Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020
Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004
Bradykinin phosphorylates ERK1/2 through epidermal growth factor receptor transactivation in human lung fibroblasts Source: Eur Respir J 2005; 26: Suppl. 49, 341s Year: 2005
Molecular mechanisms of the synergy between cysteinyl-leukotrienes and receptor tyrosine kinase growth factors on human bronchial fibroblast proliferation Source: Eur Respir J 2006; 28: Suppl. 50, 339s Year: 2006
Molecular mechanisms of the synergy between cysteinyl-leukotrienes and receptor tyrosine kinase growth factors on human bronchial fibroblast proliferation Source: Eur Respir Rev 2006; 15: 172-174 Year: 2006
Targeted therapy in nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 284–298 Year: 2009
Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020
Safety and efficacy of an inhaled epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (BIBW 2948) in COPD Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Tyrosine kinase inhibition of human pulmonary fibroblast migration Source: Eur Respir J 2005; 26: Suppl. 49, 101s Year: 2005
Inhibition of VEGF blocks TGF-β1 production through a PI3K/Akt signalling pathway Source: Eur Respir J 2008; 31: 523-531 Year: 2008
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009
The natural anticoagulant activated protein C inhibits the expression of platelet-derived growth factor in the lung Source: Eur Respir J 2002; 20: Suppl. 38, 571s Year: 2002
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
Transforming growth factor-β inhibition of lung fibroblast proliferation is mediated through prostaglandin E2 , via activation of p38 mitogen-activated protein kinase Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms Year: 2005
Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers Year: 2020
Jun kinase regulates the expression of TGF-beta induced connective tissue growth factor in human lung fibroblast Source: Annual Congress 2004 - Inflammation and remodelling in human lungs Year: 2004
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma Source: Eur Respir J 2012; 39: 366-372 Year: 2012
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020